Tempus xE Whole-Exome Tumor Sequencing

Personalized cancer technology company Tempus has introduced Tempus xE, a whole-exome sequencing panel that analyzes tumor DNA alongside a normal sample and a whole-RNA transcriptome. The new CLIA/CAP-validated assay gives researchers and clinicians a broad view of potential tumor mutations and treatment pathways, Tempus said.